Impact Factor
3.34
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.77
611 total citations
h5-index
23
h5 depth signal
Cited share
73.4%
185 of 252
Total citations
611
Citation footprint
Metric signal
2.43
External metric anchor
Self-citation
5.6%
34 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
248
United Kingdom
141
Netherlands
125
China
96
Spain
78
Citing Fields of Research
Medical Ethics
377
Healthcare Policy
243
Oncology
127
Patient Care
84
Economics
81
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,335
Articles tracked across the journal lifetime
Indexed publication set
252
185 cited publications
Last 12 months
127
10.6 publications/month
Open access share
22.8%
29 OA publications in the last year
Leading citing country
United States
248 citing publications
Leading citing field
Medical Ethics
377 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v9n1, Feb. 2009-
v9n1, Feb. 2009-
Research Focus & Classification
Indexed Subjects
Medical Ethics
Healthcare Policy
Oncology
Lung Cancer
Musculoskeletal Disorders
Allergies
Broad Categories
Pharmacology
Medical Ethics
MeSH Descriptors
Cost-Benefit Analysis.
Decision Making
Drug Therapy
Economics, Pharmaceutical
Outcome Assessment, Health Care
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/14737167.2026.2753082
Open DOI
Assessing health related quality of life of patients on maintenance hemodialysis in north-western Morocco
02
DOI 10.1080/14737167.2026.2752198
Open DOI
Expert review of pharmacoeconomics and outcomes Research: high impact articles from 2025
03
DOI 10.1080/14737167.2026.2751401
Open DOI
Cost-utility of expanded hypertension screening and treatment among adults covered by Peru’s Seguro Integral de Salud: a Markov model using national data
1 Hypertension is one of the leading preventable public health problems because of its high frequency, usually asymptomatic course, and association with major cardiovascular events, kidney disease,...
04
DOI 10.1080/14737167.2026.2746821
Open DOI
Machine learning in comparative effective research of pharmacological interventions: a scoping review
05
DOI 10.1080/14737167.2026.2746857
Open DOI
Cost-effectiveness of amivantamab plus lazertinib and osimertinib plus chemotherapy versus osimertinib monotherapy for first-line EGFR-mutated advanced non-small cell lung cancer: an updated analysis
1 According to statistics from the Global Cancer Observatory (GCO), lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths worldwide [1]. It is the third m...
06
DOI 10.1080/14737167.2026.2739076
Open DOI
Defining value criteria for outcomes-based managed entry agreements in CAR-T therapy for relapsed/refractory multiple myeloma: a multi-criteria decision analysis study
1. Multiple myeloma (MM) is a hematologic malignancy characterized by the unregulated expansion of monoclonal plasma cells within the bone marrow [1]. This aberrant proliferation of plasma cells re...
07
DOI 10.1080/14737167.2026.2746156
Open DOI
The presence of prior-effects of the Medicaid expansion on drug prescription
1. Medicaid is an essential source of state level variation in healthcare access, provider financial incentives, and safety net delivery across the United States [1–4]. Because the program is joint...
08
DOI 10.1080/14737167.2026.2746232
Open DOI
Cost-effectiveness of RIMS1 methylation-guided gastric cancer surveillance after Helicobacter pylori eradication
1. Helicobacter pylori (H. pylori) eradication reduces gastric cancer (GC) risk, but does not eliminate the need for subsequent risk assessment and management. Patients with gastric atrophy remain ...
09
DOI 10.1080/14737167.2026.2743886
Open DOI
Cost-effectiveness of microaxial flow pump versus standard of care in the management of Cardiogenic shock in Spain
1. Cardiogenic shock (CS) is a syndrome of critical end-organ hypoperfusion caused by primary cardiac dysfunction, typically defined by persistent hypotension (systolic blood pressure < 90 mmHg or ...
10
DOI 10.1080/14737167.2026.2746142
Open DOI
Wholesale, pharmacy mark-up, and retail price dynamics under a declaration-based medicine pricing reform in Kosovo
1.0 Pharmaceutical products are a unique type of health system good because of their clinical importance, regulatory protection, international trading, negotiation between buyers and suppliers, and...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.